The troubled development program for ataluren took another turn for the worse when the phase III Ataluren Confirmatory Trial (ACT CF) in nonsense mutation cystic fibrosis (nmCF) fell short across the board, missing both primary and secondary endpoints. Developer PTC Therapeutics Inc. said it was halting development of ataluren in CF.